Cubist Pharmaceuticals Inc  

(Public, NASDAQ:CBST)   Watch this stock  
Find more results forCBST
69.03
+0.12 (0.17%)
Aug 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 68.53 - 69.51
52 week 58.50 - 82.12
Open 68.92
Vol / Avg. 565,990.00/832,897.00
Mkt cap 5,227.87M
P/E 2,911.43
Div/yield     -
EPS 0.02
Shares 75.73M
Beta 0.69
Inst. own 104%
Oct 20, 2014
Q3 2014 Cubist Pharmaceuticals Inc Earnings Release (Estimated) - 4:00pm GMT-4 - Add to calendar
Sep 8, 2014
Cubist Pharmaceuticals Inc at Morgan Stanley Healthcare Conference - 10:30am GMT-4 - Add to calendar
Aug 6, 2014
Cubist Pharmaceuticals Inc at Jefferies Boston Healthcare Summit - One-on-One Meetings
Jul 22, 2014
Q2 2014 Cubist Pharmaceuticals Inc Earnings Call
Jul 22, 2014
Q2 2014 Cubist Pharmaceuticals, Inc. Earnings Release
Jun 3, 2014
Cubist Pharmaceuticals, Inc. Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 8.16% -1.76%
Operating margin 14.32% 2.50%
EBITD margin - 14.15%
Return on average assets 3.05% -0.73%
Return on average equity 6.57% -1.56%
Employees 873 -
CDP Score - -

Address

65 Hayden Avenue
LEXINGTON, MA 02421
United States - Map
+1-781-8608660 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Officers and directors

Robert J. Perez President, Chief Operating Officer, Director
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael W. Bonney Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael Tomsicek Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Thomas J. DesRosier J.D. Executive Vice President, Chief Legal and Administrative Officer and Secretary
Age: 59
Bio & Compensation  - Reuters
Steven C. Gilman Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 61
Bio & Compensation  - Reuters
Patrick Vink M.D. Senior Vice President, General Manager - International Business
Age: 50
Bio & Compensation  - Reuters
Charles Laranjeira Senior Vice President - Technical Operations
Age: 47
Bio & Compensation  - Reuters
Lorianne K. Masuoka M.D. Senior Vice President - Clinical Development and Medical Affairs, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Gregory Stea Senior Vice President - Commercial Operations
Age: 56
Bio & Compensation  - Reuters
Kenneth M. Bate Non-Executive Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters